Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria

For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Cho, Yuri, Lee, Jeong-Hoon, Lee, Dong Hyeon, Cho, Eun Ju, Yu, Su Jong, Yi, Nam-Joon, Lee, Kwang-Woong, Kim, Yoon Jun, Yoon, Jung-Hwan, Suh, Kyung-Suk
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564586/
https://ncbi.nlm.nih.gov/pubmed/28548930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17733
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars